Optimal management of metastatic bone disease

European Journal of Oncology Nursing

Volumn 11, Issue SUPPL. 2, 2007, Pages

  Major, Pierre ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Bone pain; Skeletal related events; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ARTICLE; BONE TUMOR; DRUG ADMINISTRATION; HUMAN; INCIDENCE; METASTASIS; MORBIDITY; PAIN; PALLIATIVE THERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIDAZOLES; INCIDENCE; MORBIDITY; PAIN; PALLIATIVE CARE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 34548656763     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2007.07.003     Document Type: Article

References (33)

1. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 15 Suppl. 1 (2006) S30-S40
2. Aus G., Abbou C.C., Bolla M., Heidenreich A., Schmid H.P., van Poppel H., Wolff J., and Zattoni F. EAU guidelines on prostate cancer. European Urology 48 (2005) 546-551
3. Botteman M., Barghout V., Stephens J., Hay J., Brandman J., and Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Annals of Oncology 17 (2006) 1072-1082
4. Breast Cancer Disease Site Group, Warr, D., Johnston, M., 2004. Use of Bisphosphonates in Women with Breast Cancer (Practice Guideline Report). Cancer Care Ontario, Toronto, Ontario.
5. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 27 (2001) 165-176
6. Coleman, R., Rosen, L., Gleason, D.M., Zheng, M., 2004. Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, 24-26 March 2004 (Poster 65).
7. Conte P.F., Rosen L.S., Gordon D., Zheng M., and Hei Y.-J. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Annals of Oncology 15 Suppl. (2004) iii124 (Abstract 463PD)
8. De Cock E., Hutton J., Canney P., Body J.J., Barrett-Lee P., Neary M.P., and Lewis G. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clinical Therapeutics 27 (2005) 1295-1310
9. Eastham, J., McKiernan, J., Gleason, D., Zheng, M., Saad, F., 2005. Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer: analysis by baseline pain. Presented at: American Society of Clinical Oncology, 41st Annual Meeting, Orlando, Florida, 13-17 May 2005 (Abstract 4561).
10. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., Cauley J.A., Blumenstein B.A., Albain K.S., Lipton A., and Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 21 (2003) 4042-4057
11. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., Watanabe T., Goessl C., Ohashi Y., and Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Journal of Clinical Oncology 23 (2005) 3314-3321
12. Lacy M.Q., Dispenzieri A., Gertz M.A., Greipp P.R., Gollbach K.L., Hayman S.R., Kumar S., Lust J.A., Rajkumar S.V., Russell S.J., Witzig T.E., Zeldenrust S.R., Dingli D., Bergsagel P.L., Fonseca R., Reeder C.B., Stewart A.K., Roy V., Dalton R.J., Carr A.B., Kademani D., Keller E.E., Viozzi C.F., and Kyle R.A. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic Proceedings 81 (2006) 1047-1053
13. Lipton, A., Seaman, J., Zheng, M., 2004. Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, 24-26 March 2004 (Poster 28).
14. Lipton, A., Hei, J., Coleman, R., Major, P., Smith, M., Cook, R., 2005. Breast cancer patients with persistently increased bone resorption. Presented at: ECCO 13-The European Cancer Conference, Paris, France, 30 October-3 November 2005 (Abstract 431).
15. Major P.P., and Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. American Journal of Clinical Oncology 25 Suppl. 1 (2002) S10-S18
16. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D., Yunus F., Bell R., Body J., Quebe-Fehling E., and Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 19 (2001) 558-567
17. Major P.P., Cook R.J., Chen B.-L., and Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Supportive Cancer Therapy 2 (2005) 234-240
18. Maxwell C., Swift R., Goode M., Doane L., and Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clinical Journal of Oncology Nursing 7 (2003) 403-408
19. National Comprehensive Cancer Network, 2007. Clinical Practice Guidelines in Oncology. Prostate Cancer, Version 1, 2007. Available from: 〈http://www.nccn.org〉 (accessed 28.02.07).
20. ® (pamidronate disodium) for injection for intravenous infusion [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
21. ® (zoledronic acid) injection concentrate for intravenous infusion [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
22. Paterson A.H. Bisphosphonates: biological response modifiers in breast cancer. Clinical Breast Cancer 3 (2002) 206-216 (discussion 217-218)
23. Pavlakis, N., Schmidt, R.L., Stockler, M., 2005. Bisphosphonates for breast cancer. The Cochrane Database Systematic Reviews. Art. no.: CD003474.pub2. doi:10.1002/14651858. CD003474.pub2.
24. ® (ibandronic acid) [summary of product characteristics]. Hertfordshire, UK: Roche Registration Limited.
25. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M.A., Coleman R.E., Reitsma D.J., Chen B.-L., and Seaman J.J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
26. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., de Souza P., Zheng M., Urbanowitz G., Reitsma D., and Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
27. Ruggiero S., Gralow J., Marx R.E., Hoff A.O., Schubert M.M., Huryn J.M., Toth B., Damato K., and Valero V. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice 2 (2006) 7-14
28. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., and Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of National Cancer Institute 96 (2004) 879-882
29. ® tablets [summary of product characteristics]. West Sussex, UK: Schering Health Care Limited.
30. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. Journal of Urology 169 (2003) 2008-2012
31. The British Association of Urological Surgeons, 2004. Systemic Management of Metastatic Bone Disease: Guidelines on Treatment. Available from: 〈http://www.doctoronline.nhs.uk/masterwebsite1Asp/navigation/www/specialts/BAUS_MBD%20precis%20document_180305.pdf〉 (accessed 28.02.07).
32. Wardley A., Davidson N., Barrett-Lee P., Hong A., Mansi J., Dodwell D., Murphy R., Mason T., and Cameron D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. British Journal of Cancer 92 (2005) 1869-1876
33. Weitzman R., Sauter N., Eriksen E.F., Tarassoff P.G., Lacerna L.V., Dias R., Altmeyer A., Csermak-Renner K., McGrath L., Lantwicki L., and Hohneker J.A. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Critical Reviews in Oncology Hematology 62 (2007) 148-152